TosakaASogaYIidaO. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.
2.
SchillingerMSabetiSLoeweC. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
3.
LairdJRKatzenBTScheinertD. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.
4.
BosiersMDelooseKCallaertJ. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. J Endovasc Ther. 2015;22:1–10.
5.
SchmidtAZellerTSievertH. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther. 2014;21:52–60.
6.
BrodmannMRiefPFroehlichH. Neointimal hyperplasia after SilverHawk atherectomy versus percutaneous transluminal angioplasty (PTA) in femoropopliteal stent reobstructions: a controlled, randomized pilot trial. Cardiovasc Intervent Radiol. 2013;36:69–74.
7.
LairdJRYeoKKRocha-SinghK. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv. 2012;80:852–859.
8.
LammerJZellerTHauseggerKA. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320–1327.
9.
SaxonRRChervuAJonesPA. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. J Vasc Interv Radiol. 2013;24:165–173.
10.
LensveltMMFritschyWMvan OostayenJA. Results of heparin-bonded ePTFE-covered stents for chronic occlusive superficial femoral artery disease. J Vasc Surg. 2012;56:118–125.
11.
TielliuIFZeebregtsCJVourliotakisG. Stent fractures in the Hemobahn/Viabahn stent graft after endovascular popliteal aneurysm repair. J Vasc Surg. 2010;51:1413–1418.
12.
LensveltMMGolchehrBKruseRR. The outcome of failed endografts inserted for superficial femoral artery occlusive disease. J Vasc Surg. 2013;57:415–420.
13.
SimpsonELMichaelsJAThomasSM. Systematic review and meta-analysis of additional technologies to enhance angioplasty for infrainguinal peripheral arterial occlusive disease. Br J Surg. 2013;100:1128–1137.
14.
DakeMDAnselGMJaffMR. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–2427.
15.
ZellerTDakeMDTepeG. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274–281.
16.
LiistroFAngioliPPortoI. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21:1–8.
17.
StabileEVirgaVSalemmeL. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739–1742.
